<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828503</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2008-004745-28</org_study_id>
    <nct_id>NCT00828503</nct_id>
  </id_info>
  <brief_title>Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients</brief_title>
  <acronym>Certi-CMV</acronym>
  <official_title>Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcus Saemann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized safety and efficacy study of Certican® as add-on therapy against&#xD;
      CMV disease in renal transplant recipients&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To demonstrate efficacy of Certican® as add-on therapy against CMV disease in comparison to&#xD;
      either valcyte® (valganciclovir) or cymevene® (ganciclovir) alone, evaluated by quantitative&#xD;
      measurement of CMV-DNA with PCR from the blood (qCMV-PCR)&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess safety and tolerability of Certican® in patients with CMV- disease To study the&#xD;
      effects of Certican® treatment on quality of life&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN / PHASE Prospective, single-center, randomized, parallel group, controlled, phase II&#xD;
      study.&#xD;
&#xD;
      PATIENTS / GROUPS 40 patients in 2 groups 20 patients per group Randomization ratio 1:1, no&#xD;
      stratification&#xD;
&#xD;
      INVESTIGATIONAL DRUG Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level:&#xD;
      3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to&#xD;
      the judgment of the clinical investigator - a stable degree of immunosuppression is reached;&#xD;
      thereafter Certican® trough levels will be performed at the scheduled appointments)&#xD;
&#xD;
      COMPARATIVE DRUG No therapy (add-on design&#xD;
&#xD;
      CONCOMITANT MEDICATION Allowed The concomitant immunosuppressive medication will be adjusted&#xD;
      to the additional administration of Certican®. For example, if the patient already receives&#xD;
      cyclosporine A or tacrolimus, this will be adjusted, according to the current&#xD;
      recommendations4 at the judgment of the clinical investigator&#xD;
&#xD;
      TOLERABILITY / SAFETY ENDPOINTS:&#xD;
&#xD;
      Rejection Hematocrit Platelet count WBC count Wound healing disorders Blood lipids&#xD;
      (cholesterol, triglycerides) Infections (other than CMV)&#xD;
&#xD;
      PHARMACOKINETIC / PHARMACODYNAMIC ENDPOINTS Certican® (everolimus) trough levels&#xD;
&#xD;
      STATISTICAL METHODOLOGY Primary Endpoint: CMV-load (copies/mL)&#xD;
&#xD;
      Null and alternative hypotheses:&#xD;
&#xD;
      H0 Treatment with Certican® (everolimus) in combination with valcyte® (valganciclovir) or&#xD;
      cymevene® (ganciclovir) is equal to valcyte® (valganciclovir) or cymevene® (ganciclovir)&#xD;
      alone in reducing the CMV-load in renal transplant patients with CMV-disease H1: Treatment&#xD;
      with Certican® (everolimus) in combination with valcyte® (valganciclovir) or cymevene®&#xD;
      (ganciclovir) is superior to valcyte® (valganciclovir) or cymevene® (ganciclovir) in reducing&#xD;
      CMV load (copies/mL) in renal transplant patients with CMV-disease Type-I and -II errors -&#xD;
      power. α=0.05 ß=0.2 (power 0.8) Statistical methodology ANOVA of repeated measures&#xD;
      (CMV-copies/mL), one-sided t-test of CMV load at distinct time-points, one-sided t-test of&#xD;
      the time (in weeks) until CMV-load reaches ≤600 copies/mL Sample size calculation Based on a&#xD;
      one-sided testing and a σ of 0.2 in relative changes of CMV-copies, an α=0.05 And a ß=0.2 a&#xD;
      sample size of 20 patients per group was determined. Main analysis set Per-protocol&#xD;
      (efficacy) and intention to treat (ITT) for safety Other endpoints Bonferroni corrected&#xD;
      t-tests will be performed for CMV-copies/mL at each time point of the follow-up period. The&#xD;
      time to copies ≤ 600 will also be analyzed by a t-test. All other secondary endpoints and&#xD;
      subgroup analysis will be performed in explorative intention (descriptive statistics).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relative changes in CMV-load (copies/mL), as determined by qCMV-PCR from whole blood throughout the observational period</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMV-load (copies/mL) after 1-8 weeks, in months 3, 4, 6 and 12; Time (in weeks) until the CMV-load reaches ≤600 copies/mL</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cytomegalovirus Disease</condition>
  <arm_group>
    <arm_group_label>1 Certican + Valganciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Valganciclovir alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valganciclovir will be added alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certican (everolimus) + valganciclovir</intervention_name>
    <description>Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)&#xD;
MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)</description>
    <arm_group_label>1 Certican + Valganciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)</description>
    <arm_group_label>2 Valganciclovir alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CMV-disease after renal transplantation, i.e.,(1.) CMV present in the blood, and (2.)&#xD;
             one of the following symptoms (for viral syndrome, from the American Society of&#xD;
             Transplantation recommendations for use in clinical trials1):&#xD;
&#xD;
               -  body temperature ≥ 38°C&#xD;
&#xD;
               -  new or increased significant malaise&#xD;
&#xD;
               -  leucopenia (&lt; 3500/mL)&#xD;
&#xD;
               -  atypical lymphocytosis ≥ 5%&#xD;
&#xD;
               -  thrombocytopenia (platelets &lt; 100.000/mL)&#xD;
&#xD;
          -  no other cause of symptoms/signs identified&#xD;
&#xD;
          -  informed consent of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with a known hypersensitivity to everolimus, sirolimus or any of the&#xD;
             excipients&#xD;
&#xD;
          -  administration of strong CYP3A4 Inhibitors (e.g. ketoconazole, itraconazole,&#xD;
             voriconazole, clarithromycin, telithromycin) and inducers (rifampicin), unless the&#xD;
             benefit outweighs the risk, according to the judgment of the clinical investigator&#xD;
&#xD;
          -  acute rejection episodes in the first 3 months after renal transplantation&#xD;
&#xD;
          -  active hepatitis in the previous month&#xD;
&#xD;
          -  Significant proteinuria (&gt; 0.8g/24h Urine)&#xD;
&#xD;
          -  hepatic impairment, according to the criteria defined by Bénichou et al.2: a singular&#xD;
             elevation of GPT or conjugated bilirubin to a value twice above the normal level, or a&#xD;
             combined elevation of GOT, AP, and total bilirubin, given that at least one parameter&#xD;
             is twice above the normal level&#xD;
&#xD;
          -  hematocrit &lt; 25%&#xD;
&#xD;
          -  any significant wound healing disorder (anamnestic)&#xD;
&#xD;
          -  blood white blood cell (WBC) count &lt; 3000/mL&#xD;
&#xD;
          -  platelets &lt; 50.000/mL&#xD;
&#xD;
          -  severe dyslipidemia (cholesterol &gt;300mg/dL, triglycerides &gt; 350mg/dL)&#xD;
&#xD;
          -  uncontrolled hypertension (continuous episodes of hypertension above 140/90 (WHO&#xD;
             classification and American Society of Transplantation recommendations 3) despite&#xD;
             adequate hypertensive therapy)&#xD;
&#xD;
          -  uncontrolled hyperuricemia (uric acid &gt; 8mg/dL)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  any immunosuppressive protocol which does not allow the addition of Certican®,&#xD;
             according to the judgment of the clinical investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Schmaldienst, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus D Säemann, MD</last_name>
    <phone>+431404005593</phone>
    <email>marcus.saemann@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manfred Hecking, MD</last_name>
    <phone>+431404005593</phone>
    <email>manfred.hecking@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manfred Hecking, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006 Feb;6(2):262-74.</citation>
    <PMID>16426310</PMID>
  </reference>
  <reference>
    <citation>Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990 Sep;11(2):272-6. Review.</citation>
    <PMID>2254635</PMID>
  </reference>
  <reference>
    <citation>Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000 Oct;11 Suppl 15:S1-86.</citation>
    <PMID>11044969</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>August 30, 2012</last_update_submitted>
  <last_update_submitted_qc>August 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Marcus Saemann</investigator_full_name>
    <investigator_title>Ass. Prof. Dr. Marcus Säemann</investigator_title>
  </responsible_party>
  <keyword>Certi-CMV</keyword>
  <keyword>immunosuppressive switch (to Certican)</keyword>
  <keyword>renal transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

